Document is current

Article History

Received: 16 January 2025

Accepted: 20 April 2025

First Online: 6 August 2025

Declarations

:

: RCP, MIJ, KLD, AH, VDA, and GF are employees of RTI Health Solutions, an independent nonprofit research organization which was a paid consultant to Pfizer in connection with conduct of the study and development of this manuscript. EIB, JD, CC, and BL are employees and shareholders of Pfizer, Inc., the sponsor of this study. OO is a member of advisory boards for and/or received honoraria from Pfizer, AstraZeneca, Novartis, Exact Sciences, Eisai, Daiichi Sankyo, Roche, Gilead, Eli Lilly, Merck, and Tesaro; received travel grants from Pfizer, AstraZeneca, Novartis, Eisai, Roche, Amgen, Gilead, Eli Lilly, and Menarini; and received research funding from Pfizer, Novartis, Roche, MedDiagnostics, Make2 Count, BCI, and Genomic Health. MJB has no conflicts to report. EG has received consulting fees from Roche, Pfizer, Eli Lilly, Daicchi-Sankyo, Gilead, and AstraZeneca. AW is a member of advisory boards for Amgen, AstraZeneca, Celgene, Eisai, Eli Lilly, Novartis, Pfizer, Roche, Tesaro, Sirtex, MSD, Pierre Fabre, Clovis Oncology, Organon, Seagen, Exact Sciences, Gilead, and Daiichi Sankyo.

: The RTI International Institutional Review Board deemed this study exempt from full review. The study was approved by country-specific ethics review boards in Germany, Spain, and the UK. Due to the use of deidentified/pseudonymized data, an informed consent waiver was approved.